# SUVEN — Suven Life Sciences Limited

> Suven Life Sciences Limited (SUVEN) on the NSE: 5,666 sessions of split-adjusted history from 2003.

Canonical: https://patternsradar.com/s/SUVEN

## Latest session

- Close: 373.15 INR (-0.12% on the day), 2026-08-21
- Delivery: 31.76% of volume taken to demat (20-day average 37.51%)
- Volume: 18.53L shares, turnover ₹69.2Cr
- Relative volume: 2.14× of its own 20-day average

## Technicals

- RSI(14): 65.9
- ATR(14): 20.81
- SMA 50: 312.97, SMA 200: 212.96
- 52-week range: 124.11 – 389.9 (-4.3% from the high)

## Performance

- 1 week 9%, 1 month 17.71%, 3 months 40.57%
- 6 months 150.55%, 1 year 60.67%

## Fundamentals

- Market cap: 10,543.8 crore
- P/E (TTM): — — NULL when trailing earnings are negative or unfiled, never a misleading number
- EPS (TTM): -12.47 INR, split-adjusted to match the price series
- Revenue growth: 91.02% YoY, 134.58% QoQ
- Profit growth: — YoY, — QoQ

Compound annual growth, trailing-twelve-month against the same measure N years earlier:

| Window | Revenue | Profit |
| --- | --- | --- |
| 2y | -0.49% | — |
| 3y | -13.88% | — |
| 4y | -9.91% | — |
| 5y | -8.91% | — |
| 6y | -44.05% | — |

## Quarterly results

Last 8 filed quarters, consolidated basis, in rupees crore as filed.

| Quarter | Revenue | Total expenses | Profit before tax | Net profit | EPS | Net margin |
| --- | --- | --- | --- | --- | --- | --- |
| 2024-09-30 | 2.6 | 56.3 | -49.6 | -49.6 | -2.27 | -1,929.49% |
| 2024-12-31 | 1.6 | 42.4 | -39.1 | -39.1 | -1.79 | -2,429.75% |
| 2025-03-31 | 1.5 | 46.6 | -43.9 | -43.9 | -2.02 | -2,995.56% |
| 2025-06-30 | 1.9 | 54 | -51.5 | -51.5 | -2.36 | -2,759.78% |
| 2025-09-30 | 0.9 | 82 | -77.3 | -77.3 | -3.48 | -8,410.56% |
| 2025-12-31 | 2.8 | 107.5 | -101.9 | -101.9 | -4.55 | -3,628.79% |
| 2026-03-31 | 1.5 | 53.9 | -45.6 | -45.6 | -2.02 | -2,999.51% |
| 2026-06-30 | 3.6 | 138.7 | -127.6 | -127.6 | -4.84 | -3,578.73% |

A quarterly filing with NSE carries a profit and loss only. There is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure in this dataset. EPS is restated onto the split-adjusted basis the price series uses; every rupee figure is exactly as filed.

## Shareholding

As filed for 2026-07-08:

- Promoter: 65.47%
- Public: 34.53%

Institutional and pledge percentages come from a filing stage whose backfill has reached about 1% of instruments, so they are absent here rather than zero.

## Recent filings

- 2026-08-06: results for 2026-06-30 both — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_183047_06082026142720_iXBRL_WEB.html
- 2026-07-20: shareholding for 2026-07-08 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1697600_20072026091938_WEB.xml
- 2026-07-16: shareholding for 2026-06-30 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1693748_16072026100839_WEB.xml
- 2026-05-13: results for 2026-03-31 both — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_157221_13052026173515_iXBRL_WEB.html
- 2026-04-16: shareholding for 2026-03-31 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1652069_16042026022900_WEB.xml
- 2026-03-13: shareholding for 2026-03-06 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1635555_13032026050236_WEB.xml
- 2026-01-29: results for 2025-12-31 both — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_138362_29012026150240_iXBRL_WEB.html
- 2026-01-13: shareholding for 2025-12-31 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1599606_13012026023731_WEB.xml

Dated by the day the company broadcast the filing. 124 events are indexed for this instrument.

## About the instrument

- Listed: 2003-10-24 — latest session 2026-08-21 (5,666 sessions)
- ISIN: INE495B01038
- Series: EQ
- Liquidity rank: #634 by 20-day average turnover — not index membership

Delivery figures come from NSE's daily reports and are unavailable for older sessions. Prices are end-of-day, split- and bonus-adjusted, from the eod2 dataset.

Charts and the full bar history are on the rendered page: https://patternsradar.com/s/SUVEN.